In early-phase clinical trials, brentuximab vedotin demonstrated impressive single-agent activity in CD30-positive hematological malignancies including HL and anaplastic large-cell lymphoma (ALCL). This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.